ScholarLens Back to search
2007•Journal watchRequires access

Again, Vioxx Is Shown to Increase Cardiovascular Risk

Harlan M. Krumholz, Sm

Open publisher page 0 citations

Abstract

Data on rofecoxib (Vioxx), a COX-2 inhibitor that was withdrawn from the market in 2004 amid concerns about cardiovascular risk, is still accruing.

About this research paper

What this paper is about

Data on rofecoxib (Vioxx), a COX-2 inhibitor that was withdrawn from the market in 2004 amid concerns about cardiovascular risk, is still accruing.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Data on rofecoxib (Vioxx), a COX-2 inhibitor that was withdrawn from the market in 2004 amid concerns about cardiovascular risk, is still accruing.

Key concepts: Medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Again, Vioxx Is Shown to Increase Cardiovascular Risk — Research Paper | ScholarLens